Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Lymph Node Excision (LNEx) for Patients With Stage III Melanoma With One Clinically Positive Node: Excision of Lymph Node Trial [EXCILYNT]

NCT05839912 is registered in ClinicalTrials.gov with Craig L Slingluff, Jr as lead sponsor.

NCT NCT05839912
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05839912 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Lymph Node Excision (LNEx) for Patients With Stage III Melanoma With One Clinically Positive Node: Excision of Lymph Node Trial [EXCILYNT]
Lead sponsor
Craig L Slingluff, Jr
Phase
Not applicable
Overall status
Recruiting
Start date
September 6, 2023
Completion date
September 1, 2028
Enrollment
66 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma